The Generic Drugs Market: 2020 – 2030 - Opportunities, Challenges, Strategies & Forecasts

Release Date: October 2020
Number of Pages: 413
Number of Tables and Figures: 60

Synopsis: A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights.

Already prevalent in the United States, Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. Moreover generic drugs are witnessing high growth rates in emerging markets such as China, India, Brazil etc. 

SNS Research estimates that the market for generic drugs will account for $489 Billion in revenue by the end of 2020. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years which is driven by the increasing incidence of chronic diseases, an aging global population and the necessity to drive down cost of expensive brand name drugs for patients. The market is expected to grow at a CAGR of 7.3% between 2020 and 2025, driven by growth in both established and developing markets.
​
The “Generic Drugs Market: 2020 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. ​The report also presents market size forecasts for generic drugs from 2020 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. 

​The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
For a Sample and Table of Contents please contact i[email protected]

Pricing: The report is available for the following price:

Single User License: USD 2,500

Company Wide License (Single Site): USD 3,500

Company Wide License (Global Site): USD 6,500

Key Findings:
The report has the following key findings:
  • Generic drugs will account for $489 Billion in revenue by the end of 2020. The market is further expected to grow at a CAGR of 7.3% over the next five years.
  • The market is continuing to consolidate with several prominent acquisitions such as Celgene’s takeover by Bristol-Myers Squibb for $74 billion and Japanese pharmaceutical company Takeda’s acquisition in a deal of $62 billion.
  • Approval rate of generics and biosimilars is on the incline, as FDA approved a record-breaking number of new drugs over the last 3 years, including a high number of “first generics”. As of Q3 2020 a total of 28 biosimilars are FDA approved.
  • In order to overcome low margins, some generic drug developers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 28% of all spending on generic drugs.
  • Regulators and lawmakers, particularly in Europe & USA, have begun taking a tougher line on anti-competitive practices prevalent in the generics ecosystem such as: "pay-for-delay" settlements, where an originator pharmaceutical company pays generic drug developers to stay out of the market.
  • Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for nearly $21 Billion in revenue by the end of 2020. 

Topics Covered:
The report covers the following topics:
  • Generic drugs ecosystem
  • Market drivers and barriers
  • Technology, economics and key trends
  • Pure, branded and super generics
  • Analysis of key therapeutic areas and leading generic drugs
  • Regulatory landscape of generic drugs throughout the globe
  • Industry roadmap and value chain
  • Profiles and strategies of 265 leading ecosystem players, including generic drug developers and originator pharmaceutical companies
  • Strategic recommendations for ecosystem players - Market analysis and forecasts from 2020 till 2030

Historical Revenue & Forecast Segmentation:
Market forecasts are provided for each of the following submarkets and their subcategories:
  • Brand Classification
    • Pure (Non-Branded) Generics
    • Branded Generics
    • Super Generics
​
  • Therapeutic Area
    • ​Antibiotics
    • Cardiovascular & Hypertension
    • CNS (Central Nervous System)
    • Dermatology
    • Diabetes
    • Gastrointestinal
    • Hormonal Drugs
    • Oncology
    • Pain Relief
    • Respiratory
    • Rheumatology
    • Others\

  • Regional Markets
    • ​Asia Pacific
    • Europe
    • Middle East & Africa
    • North America
    • Latin & Central America

  • Country Markets
    • ​Brazil
    • Canada
    • China
    • Egypt
    • France
    • Germany
    • Greece
    • India
    • Israel
    • Italy
    • Japan
    • Mexico
    • Netherlands
    • Poland
    • Portugal
    • Russia
    • Saudi Arabia
    • South Africa
    • South Korea
    • Spain
    • Switzerland
    • Taiwan
    • Turkey
    • UK
    • USA

Key Questions Answered:
The report provides answers to the following key questions:
  • How big is the generic drugs opportunity?
  • What trends, challenges and barriers are influencing its growth?
  • How is the ecosystem evolving by segment and region?
  • What will the market size be in 2025 and at what rate will it grow?
  • How has COVID-19 impacted the supply chain of generic drugs in the US?
  • Which countries and submarkets will see the highest percentage of growth?
  • How big is the market for generic cancer drugs?
  • How does regulation impact the adoption of generic drugs?
  • How will branded and super generics impact revenue prospects?
  • Who are the key market players and what are their strategies?
  • How will patent expirations of biologics impact the market?
  • What are the future prospects of approved and non-approved biosimilar drugs?
  • What strategies should generic drug developers and originators adopt to remain competitive?

List of Companies Mentioned:
The following companies and organizations have been reviewed, discussed or mentioned in the report:

AAA (Association for Accessible Medicines)
Abbott Laboratories
AbbVie
Accord Healthcare
Aceto Corporation
Aché Laboratórios Farmacêuticos
Acino International
Actavis
Actelion
Adcock Ingram
Adello Biologics
Aenova Group
Aesica Pharmaceuticals
AET (Alfred E Tiefenbacher) Group
AET BioTech (AET BioTechnology)
Ajanta Pharma
Ajinomoto Group
Akron Pharmaceuticals
Alembic Pharmaceuticals
Alexion Pharmaceuticals
Alfa Wasserman
Alkem Laboratories
Allergan
Almirall
Alvogen
Alvotech
AMA (African Medicines Agency)
Amega Biotech
Amgen
Amneal Pharmaceuticals
AMRI (Albany Molecular Research, Inc.)
ApoPharma
Apotex
Arch Pharmalabs
Aryogen
ASKA Pharmaceutical Company
Aspen Holdings
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Auxilium Pharmaceuticals
Avadel Pharmaceuticals
Bausch & Lomb
Baxalta
Baxter International
Bayer
BD (Becton, Dickinson and Company)
Berlin Chemie
Bespak
Biocad
Biocon
Biodel
Biogaran
Biogen
Biogen Laboratorios
Bionovis
BioOutsource
Biopartners Holdings
BioReference Laboratories
Biosidus
Biosintez
Biotechpharm
Bioton
BioXpress Therapeutics
BMS (Bristol-Myers Squibb)
Boehringer Ingelheim
Bolder BioTechnology
Boots UK
BPI (Breckenridge Pharmaceutical Inc.)
Breckenridge Pharmaceutical
Cadila Pharmaceuticals
Cambrex Corporation
Cassara Biotech
CDSCO (Central Drug Standards and Control Organization, India)
Cedarburg Pharmaceuticals
Celgene Corporation
Celltrion Group
Celltrion Healthcare
CFDA (China Food and Drug Administration)
CFR Pharmaceuticals
Changchun High & New Technology Industries Group
Chemo Group
Chengdu Kang Hong Pharmaceutical Group Company
Chiesi Farmaceutici
China Medical System Holdings
Chong Kun Dang Pharmaceutical Corporation
Chongqing Zhifei Biological Products Company
Chugai Pharmaceutical Company
Cipla
Cipla BioTec
Citron Pharma
Claris Injectables
Claris Lifesciences
Claris Otsuka
Coherus BioSciences
Consort Medical
CPGJ (Shanghai CP Guojian Pharmaceutical Company)
CR Pharmaceutical (China Resources Pharmaceutical Group)
Creative BioMart
CSPC Pharmaceutical Group
Cypress Pharmaceutical
Daiichi Sankyo
Daiichi Sankyo Espha
Dong-A Pharmaceutical Company
Dong-A Socio-Holdings Company
Dong-A ST
Dr. Reddy's Laboratories
DS Pharma Promo Company
Dusa Pharmaceuticals
EGA (European Generic Medicines Association)
Egis Pharmaceuticals
Eisai Company
Eli Lilly and Company
Elmed Eisai Company
EMA (European Medicines Agency)
Emcure Pharmaceuticals
EMS
Endo International
Endo Pharmaceuticals
Epirus Biopharmaceuticals
ESTEVE Farma
ESTEVE Group
Eurofarma Laboratorios
Exeltis
Ferring Pharmaceuticals
Flamel Technologies
Formycon
Fresenius Kabi
Fuji Pharma Company
Fujifilm Corporation
Fujifilm Holdings Corporation
Fujifilm Kyowa Kirin Biologics
Fujifilm Pharma Company
Gador
Galderma
Galenika
GAVIS Pharmaceuticals
Gedeon Richter
Gene Techno Science
Genepharm
Genexine
Gennova
Genomma Lab International
Genor Biopharma
GGL (Glenmark Generics Limited)
Gilead Sciences
Gland Pharma
Glenmark Pharmaceuticals
Globalpharma
Green Cross Corporation
Grifols
Grünenthal Group
GSK (GlaxoSmithKline)
Guangdong BeiKang Pharmaceutical Company
Guangdong Wens Dahuanong Biotechnology Company
Guangxi Wuzhou Pharmaceutical Group Company
Guangxi Wuzhou Zhongheng Group Company
Guangzhou Pharmaceuticals Corporation
Guizhou Xinbang Pharmaceutical Company
Guizhou Yibai Pharmaceutical Company
Haisco Pharmaceutical Group
Hameln Pharmaceuticals
Handa Pharmaceuticals
Hanmi Pharmaceutical Company
Hanwha Chemical Corporation
Hanwha Group
Harbin Gloria Pharmaceuticals Company
Health Canada
HEC Pharm
Heilongjiang ZBD Pharmaceutical Company
Helvetic BioPharma
Heritage Pharmaceuticals
Hetero
Hikma Pharmaceuticals
Hi-Tech Pharmacal
HMP (Harvest Moon Pharmaceuticals)
Horizon Pharma
Hospira
HPGC (Harbin Pharmaceutical Group Company)
Huadong Medicine Company
Hualan Biological Engineering
Humanwell Healthcare Group Company
Hybio Pharmaceutical Company
Hypermarcas
ILKO Pharmaceuticals
ILKOGEN
Impax Laboratories
InSite Vision
Intas Pharmaceuticals
Ipsen
ISU ABXIS
Janssen
Jazz Pharmaceuticals
Jiangsu Hengrui Medicine Company
Jiangsu Wuzhong Industrial Company
Jiangsu Wuzhong Pharmaceutical Group Corporation
Jiangzhong Pharmaceutical Company
Jilin Aodong Medicine Industry Group Company
Johnson & Johnson
Joincare Pharmaceutical Group Industry Company
JT (Japan Tobacco)
Kaken Pharmaceutical Company
Kalbe (PT Kalbe Farma)
Kaneka Corporation
Kowa Company
Kremers Urban Pharmaceuticals
Krka
Kyowa Hakko Kirin Company
Kyowa Pharmaceutical Industry Company
Laboratorios Bagó
Laboratorios Beta
Laboratorios Roemmers
Landsteiner Scientific
Lannett Company
Leadiant Biosciences
LEO Pharma
LG Chem
LG Life Sciences
Lil Therapeutics
Litha
Livzon Pharmaceutical Group Company
Lucid Pharma
Lundbeck
Lupin
Luye Pharma Group
mAbxience
Mallinckrodt
Mankind Pharma
Maruho Company
Matrix Laboratories
Mayne Pharma Group
Meda
MEDICE Arzneimittel Pütter
Medley Farma
Medquímica
Mega Pharma
Meiji Holdings Company
Meiji Seika Pharma Company
Menarini Group
Merck and Co.
Merck KGaA
Merck Serono
Merz Pharma
MFDS (Korean Ministry of Food and Drug Safety)
Ministry of Health (Brazil)
Ministry of Health, Labour and Welfare (Japan)
Mitsubishi Chemical Holdings Corporation
Mitsubishi Tanabe Pharma Corporation
Mitsui & Company
Mitsui Group
Mochida Pharmaceutical Company
Momenta Pharmaceuticals
Mylan
Natco Pharma
NCPC (North China Pharmaceutical Group Corporation)
Nestlé Skin Health
Nichi-Iko Pharmaceutical Company
Nippon Kayaku
Nippon Shinyaku
Nipro Corporation
Nipro Pharma Corporation
Nobel Ilac
Novartis
Novel Laboratories
Novo Nordisk
OLIC (Thailand)
Oncobiologics
Ono Pharmaceutical Company
Orion
Orygen Biotecnologia
Osaka Synthetic Chemical Laboratories
Otsuka Holdings Company
Otsuka Pharmaceutical Company
Otsuka Pharmaceutical Factory
Paladin Labs
Par Pharmaceutical
Pengqi Technology Development Company
Pensa Dose
Pensa Pharma
Perrigo Company
Pfenex
Pfizer
Pharma Dynamics
Pharmascience
Pharmstandard
Pierre Fabre (Laboratoires Pierre Fabre)
Piramal Enterprises
Piramal Group
PlantForm Corporation
Polpharma
Prasco Laboratories
PregLem
Probiomed
Protalix Biotherapeutics
Purdue Pharma
Qilu Pharmaceutical Company
Qualitest and Vintage Pharmaceuticals
Ranbaxy Laboratories
Recordati
Regeneron Pharmaceuticals
Rising Pharmaceuticals
RLS (Reliance Life Sciences)
Roche Holding (F. Hoffmann-La Roche)
Roxane Laboratories
Royalty Pharma
R-Pharm
RPI Finance Trust
Sagent Pharmaceuticals
Salix Pharmaceuticals
Samsung Bioepis
Samsung BioLogics
Samsung Group
Sandoz
Sanofi
Sanofi Generics
Santen Pharmaceutical Company
Sanwa Kagaku Kenkyusho Company
Sartorius
Sartorius Stedim Biotech
Sawai Pharmaceutical Company
ScinoPharm Taiwan
SEDICO Pharmaceutical Company
Seikagaku Corporation
Selcuklu Holding
Sequent Scientific
Servier (Les Laboratoires Servier)
Shanghai Celgen Biopharmaceutical Company
Shanghai Fosun Pharmaceutical Group Company
Shanghai Henlius Biotech Company
Shenzhen Neptunus Group Company
Shenzhen Salubris Pharmaceuticals Company
Shijiazhuang Yiling Pharmaceutical Company
Shionogi & Company
Shire
Sichuan Kelun Pharmaceutical Company
Sihuan Pharmaceutical Holdings Group
Sinopharm (China National Pharmaceutical Group Corporation)
SL Pharm (Beijing SL Pharmaceutical Company)
SOMAR Pharmaceutical Group
STADA Arzneimittel
Stelis Biopharma
Strides Arcolab
Sumitomo Dainippon Pharma Company
Sun Pharma (Sun Pharmaceutical Industries)
Supera Farma Laboratorios
Suzuken Company
Taisho Pharmaceutical Holdings Company
Taiyo Pharmaceutical Industry Company
Takeda Pharmaceutical Company
Tanabe Seiyaku Hanbai Company
Taro Pharmaceutical Industries
Tecnoquimicas
Teijin Group
Teijin Pharma
Temmler Pharma
Teva Pharmaceutical Industries
Teva Takeda Yakuhin
Teva-Kowa Pharma Company
TGA (Therapeutic Goods Administration, Australia)
Thar Pharmaceuticals
The Medicines Company
Tianjin Chase Sun Pharmaceutical Company
Tianjin Zhongxin Pharmaceutical Group Corporation
Tonghua Dongbao Pharmaceutical Company
Torii Pharmaceutical Company
Torrent Group
Torrent Pharmaceuticals
Towa Pharmaceutical Company
U.S. FDA (Food and Drug Administration)
UCB Group
Unilab
United Therapeutics Corporation
URL Pharma
USV
Valeant Pharmaceuticals International
Varifarma
Ventana Medical Systems
Veropharm
Vertex Pharmaceuticals
Viatris
Walvax Biotechnology Company
West-Ward Pharmaceuticals
WHO (World Health Organization)
Wockhardt
Xbrane Biopharma
Yichang Chang Jiang Pharmaceutical Company
YRPG (Yangtze River Pharmaceutical Group)
Zhejiang Conba Pharmaceutical Company
Zhejiang Hisoar Pharmaceutical Company
Zhejiang Hisun Pharmaceuticals Company
Zhejiang Huahai Pharmaceutical Company
Zydus Group (Cadila Healthcare)
Zymenex